{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://www.flagtherapeutics.com/#organization",
      "name": "FLAG Therapeutics",
      "url": "https://www.flagtherapeutics.com/",
      "description": "FLAG-003, the company’s lead candidate for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG - a rare and fatal pediatric cancer) and glioblastoma multiform (GBM), is on-track to enter Phase 1 clinical development in early 2026 in children with DIPG. Raleigh, North Carolina Info@FlagTherapeutics.com 919.294.6472 Privacy Policy Contact Us"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/flag-therapeutics#asg",
      "name": "FLAG Therapeutics ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/flag-therapeutics",
      "isPartOf": {
        "@id": "https://www.flagtherapeutics.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}